Self-reported compliance with osteoporosis medication-Qualitative aspects and correlates

Maturitas

Volumn 60, Issue 3-4, 2008, Pages 223-229

  Vytrisalova, Magda ^a   Blazkova, Sarka ^a   Palicka, Vladimir ^b   Vlcek, Jiri ^a   Cejkova, Marketa ^a   Hala, Tomas ^c   Pavelka, Karel ^b   Koblihova, Helena ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Pardubice Regional Hospital   (Czech Republic)

Author keywords

Co medication; Compliance; Knowledge; Osteoporosis; Self report

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PREVALENCE; QUESTIONNAIRE; SELF REPORT;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; DIETARY SUPPLEMENTS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; VITAMIN D;

EID: 52349110285     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.07.009     Document Type: Article

References (44)

1. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17 (2006) 1726-1733
2. Lips P., and van Schoor N.M. Quality of life in patients with osteoporosis. Osteoporos. Int. 16 (2005) 447-455
3. Johnell O., Kanis J.A., Odén A., et al. Mortality after osteoporotic fractures. Osteoporos. Int. 15 (2004) 38-42
4. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., and Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner. Res. 22 (2007) 465-475
5. Caro J.J., Ishak K.J., Huybrechts K.F., Raggio G., and Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int 15 (2004) 1003-1008
6. McCombs J.S., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
7. Huybrechts K.F., Ishak K.J., and Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38 (2006) 922-928
8. Compston J.E., and Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 368 (2006) 973-974
9. Seeman E., Compston J., Adachi J., et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos. Int. 18 (2007) 711-719
10. Reginster J.Y., Rabenda V., and Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38 4 Suppl. 1 (2006) S2-S6
11. Martin S., Schneider B., Heinemann L., et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49 (2006) 271-278
12. Cramer J.A., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among woman with postmenopausal osteoporosis. Curr. Med. Res. Opin. 21 (2005) 1453-1460
13. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo. Clin. Proc. 80 (2005) 56-61
14. Carr A.J., Thompson P.W., and Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos. Int. 17 (2006) 1638-1644
15. Weycker D., Macarios D., Edelsberg J., and Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int. 17 (2006) 1645-1652
16. Emkey R.D., and Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am. J. Med. 119 4 Suppl. 1 (2006) S18-S24
17. National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. January, 2005. Available from http://www.nice.org.uk/nicemedia/pdf/TA087guidance.pdf. [last accessed 20 June 2008].
18. Bayer M., Blahoš J., Broulík P., et al. Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy. Osteol. Bull. 8 (2003) 8-13
19. Papaioannou A., Ioannidis G., Adachi J.D., et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos. Int. 14 (2003) 808-813
20. Curtis J.R., Westfall A.O., Allison J.J., Freeman A., and Saag K.G. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos. Int. 17 (2006) 1268-1274
21. Solomon D.H., Avorn J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med 165 (2005) 2414-2419
22. Hamilton B., McCoy K., and Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14 (2003) 259-262
23. McHorney C.A., Schousboe J.T., Cline R.R., and Weiss T.W. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr. Med. Res. Opin. 24 (2008) 707
24. Vytrisalova M., Kubena A., Vlcek J., Palicka V., Hala T., and Pavelka K. Knowledge of osteoporosis correlated with hormone therapy use and health status. Maturitas 56 (2007) 21-29
25. Anonymous. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. Vol. 843. Geneva: World Health Organisation; 1994.
26. Pande KC, Takats D, Kanis JA, Edwards V, Slade P, McCloskey EV. Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis. Maturitas 2000;37:75-81. http://linkinghub.elsevier.com/retrieve/pii/S0378512200001651.
27. Gold D.T., and Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr. Osteoporos. Rep. 4 (2006) 21-27
28. Dezii C.M. Persistence with drug therapy: a practical approach using administrative claims data. Manage. Care. 10 (2001) 42-45
29. Rossini M., Bianchi G., Di-Munno O., et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos. Int. 17 (2006) 914-921
30. Gregoire J., Moisan J., Guibert R., Ciampi A., and Milot A. Predictors of self-reported noncompliance with antihypertensive drug treatment: a prospective cohort study. Can. J Cardiol. 22 (2006) 323-329
31. Horsman J., Furlong W., Feeny D., and Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual. Life Outcomes 1 (2003) 54
32. Waterhouse D.M., Calzone K.A., Mele C., and Brenner D.E. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin. Oncol. 11 (1993) 1189-1197
33. Lu M., Safren S.A., Skolnik P.R., et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 12 (2008) 86-94
34. Hamilton G.A. Measuring adherence in a hypertension clinical trial. Eur. J Cardiovasc. Nurs. 2 (2003) 219-228
35. Hugen P.W., Langebeek N., Burger D.M., et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir. Immune. Defic. Syndr. 30 (2002) 324-334
36. Chan Y.M., and Molassiotis A. The relationship between diabetes knowledge and compliance among Chinese with non-insulin dependent diabetes mellitus in Hong Kong. J Adv. Nurs. 30 (1999) 431-438
37. Tettersell M.J. Asthma patients' knowledge in relation to compliance with drug therapy. J Adv. Nurs. 18 (1993) 103-113
38. Alm-Roijer C., Stagmo M., Uden G., and Erhardt L. Better knowledge improves adherence to lifestyle changes and medication in patients with coronary heart disease. Eur. J. Cardiovasc. Nurs. 3 (2004) 321-330
39. Van der Wal M.H., Jaarsma T., Moser D.K., Veeger N.J., van Gilst W.H., and van Veldhuisen D.J. Compliance in heart failure patients: the importance of knowledge and beliefs. Eur. Heart. J. 27 (2006) 434-440
40. Vermeire E., Hearnshaw H., Van-Royen P., and Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin. Pharm. Ther. 26 (2001) 331-342
41. Weiss L., French T., Finkelstein R., Waters M., Mukherjee R., and Agins B. HIV-related knowledge and adherence to HAART. AIDS-Care 15 (2003) 673-679
42. Grant R.W., Devita N.G., Singer D.E., and Meigs J.B. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 26 (2003) 1408-1412
43. Bayly J.R., Hollands R.D., Riordan-Jones S.E., et al. Prescribed vitamin D and calcium preparations in patients treated with bone remodelling agents in primary care: a report of a pilot study. Curr. Med. Res. Opin. 22 (2006) 131-137
44. Sleath B., Wurst K., and Lowery T. Drug information sources and antidepressant adherence. Community Ment. Health J 39 (2003) 359-368